A61K 47/64
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a
Official title: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
A61K47/64 (Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a) appears on 5,482 US grants and 9,358 published applications in this corpus.
Search patents in A61K- Granted patents
- 5,482
- Published applications
- 9,358
- Assignees
- 3,160
- Inventors
- 15,178
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 8 | 0 |
| 1983 | 3 | 0 |
| 1984 | 2 | 0 |
| 1985 | 3 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 9 | 0 |
| 1989 | 8 | 0 |
| 1990 | 8 | 0 |
| 1991 | 10 | 0 |
| 1992 | 23 | 0 |
| 1993 | 27 | 0 |
| 1994 | 30 | 0 |
| 1995 | 46 | 0 |
| 1996 | 37 | 0 |
| 1997 | 61 | 0 |
| 1998 | 90 | 0 |
| 1999 | 79 | 0 |
| 2000 | 81 | 0 |
| 2001 | 78 | 20 |
| 2002 | 82 | 133 |
| 2003 | 70 | 235 |
| 2004 | 71 | 222 |
| 2005 | 64 | 205 |
| 2006 | 103 | 224 |
| 2007 | 81 | 173 |
| 2008 | 88 | 211 |
| 2009 | 86 | 246 |
| 2010 | 111 | 301 |
| 2011 | 126 | 289 |
| 2012 | 123 | 272 |
| 2013 | 164 | 296 |
| 2014 | 231 | 386 |
| 2015 | 263 | 453 |
| 2016 | 260 | 498 |
| 2017 | 325 | 431 |
| 2018 | 302 | 495 |
| 2019 | 326 | 520 |
| 2020 | 343 | 557 |
| 2021 | 337 | 568 |
| 2022 | 297 | 589 |
| 2023 | 278 | 558 |
| 2024 | 267 | 586 |
| 2025 | 297 | 552 |
| 2026 | 173 | 338 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids1,111
- A61K 47/646The entire peptide or protein drug conjugate elicits an immune response984
- A61K 47/643Albumins687
- A61K 47/6415Toxins or lectins506
- A61K 47/6425The peptide or protein in the drug conjugate being a receptor352
- A61K 47/642The peptide or protein in the drug conjugate being a cytokine327
- A61K 47/6435The peptide or protein in the drug conjugate being a connective tissue134
- A61K 47/644Transferrin108
All 10 subgroupsShow fewer
Recent patents
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Bimetallic fluorescent nanocomposites for cancer theranostics29 Sep 2026US 12,746,598 B2Council of Scientific and Industrial Research
- Liquid formulation22 Sep 2026US 12,741,011 B2Hanmi Pharm. Co., Ltd.
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Polypeptide derivative and preparation method thereof15 Sep 2026US 12,734,243 B2Ningbo Kunpeng Biotech Co., Ltd.
- Antibody recruiting molecules for the treatment of coronavirus disease-198 Oct 2026US 2026/0306644 A1Biohaven Therapeutics Ltd.
- Modular platform for molecular conjugation8 Oct 2026US 2026/0306645 A1CamBrixBio Ltd
- Targeted lipid nanoparticles for treating central nervous system injuries8 Oct 2026US 2026/0306665 A1Wisconsin Alumni Research Foundation
- Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an il-2 mutant and a cd80 extracellular domain8 Oct 2026US 2026/0308251 A1Gi Innovation, Inc.
- A proimmunotoxin therapeutic nanoplatform against cancer8 Oct 2026US 2026/0308268 A1The Regents of the University of California
Most cited
By later US patents
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers896US 5,410,016 ABoard of Regents, The University of Texas System · 1995
- Collagen-polymer conjugates778US 5,162,430 ACollagen Corporation · 1992
- Gels for encapsulation of biological materials587US 5,858,746 ABoard of Regents, The University of Texas System · 1999
- Cationic lipids for intracellular delivery of biologically active molecules586US 5,459,127 AVical Incorporated · 1995
- Cationic lipids for intracellular delivery of biologically active molecules545US 5,264,618 AVical Incorporated · 1993